Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first quarter 20245 investor ...

"The Novo Nordisk Foundation is increasing its influence and has appointed its chairman, Lars Rebien Sørensen, as an observer ...

BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the leadership change ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...

Detailed price information for Lifemd Inc 8.875% Series A (LFMDP-Q) from The Globe and Mail including charting and trades.

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

The future is powered by artificial intelligence ... In its first-quarter 2025 investor letter, Polen Focus Growth Strategy highlighted stocks such as Novo Nordisk A/S (NYSE:NVO).